Anna Maria de Costa, MD
Radiation Oncology · Santa Fe, NMNPI 1407261522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,040, more than ten times the $56 reported in 2019. Among radiation oncology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$328
- Exelixis Inc.$115
- Boston Scientific$107
- Johnson & Johnson$79
- Daiichi Sankyo Inc.$71
- Incyte Corporation$69
- plus $666 from 21 others
What the payments were for
- Food & beverage$1,435100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $328 |
| Exelixis Inc. | 5 | $115 |
| Boston Scientific | 5 | $107 |
| Johnson & Johnson | 4 | $79 |
| Daiichi Sankyo Inc. | 3 | $71 |
| Incyte Corporation | 3 | $69 |
| AstraZeneca | 4 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| AbbVie | 2 | $54 |
| Geron Corporation | 2 | $45 |
| Novocure Inc. | 2 | $44 |
| Sobi, Inc | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| Sanofi | 1 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Merck | 1 | $28 |
| Genmab U.S., Inc. | 1 | $27 |
| Bayer | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $22 |
| Pfizer | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
How this compares
$1,435 in reported general payments places this provider in the 90th percentile of 24 radiation oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 66 | $1,403 |
| Tamsulosin Hcl | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Santa Fe
- Bryan GossSanta Fe$6K
- Mary RoseSanta Fe$868
- Gregg FranklinAlbuquerque$75K
- Mary BucciAlbuquerque$1K
- Patrick BeagenAlbuquerque$1K
- Thomas SchroederAlbuquerque$811
- Jeremiah JohnsonAlbuquerque$770
- David LeeAlbuquerque$674
- Peter BernatAlamogordo$669
- Jason CallLas Cruces$558
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.